H.B. Fuller moves to buy Advanced Medical Solutions

Medical devices on surgical tray symbolize healthcare M&A deal and stock move in medical sector

Key Points

01H.B. Fuller launches £2.85 per share cash offer for AMS
02Deal values AMS at about £715m enterprise value, or $942.1m
03Completion targeted by end-2026, pending approvals
04Acquisition would form new medical unit and AMS shares jumped

H.B. Fuller announces cash offer for AMS

H.B. Fuller has made a recommended cash offer to acquire Advanced Medical Solutions Group plc at £2.85 per share. The proposal values the U.K.-listed wound-care and medical technology company at an enterprise value of approximately £715 million, which equates to about $942.1 million including debt.

The offer is structured entirely in cash, giving Advanced Medical Solutions’ shareholders the option to exit their investment at a set price above the company’s latest undisturbed trading levels. The deal represents a significant cross-border move by H.B. Fuller into the U.K. healthcare and medical devices space.

Timeline and conditions for completion

The companies expect the transaction to complete by the end of the 2026 calendar year. This timetable is contingent on approval by Advanced Medical Solutions’ shareholders, as well as on receiving regulatory clearances and satisfying other customary closing conditions.

The extended expected closing window highlights the role of regulatory and shareholder processes in finalising large international healthcare-related acquisitions. Until completion, both businesses continue to operate independently.

Strategic rationale and new medical unit

H.B. Fuller states that acquiring Advanced Medical Solutions will expand its capabilities in medical adhesives. The deal would add surgical adhesive technologies, including tissue-bonding adhesives, as well as medical tapes and dressings and formulated biosurgicals to H.B. Fuller’s existing portfolio.

Following completion, the acquired operations are planned to be combined into a new global business unit within H.B. Fuller. Management expects this medical-focused unit to represent roughly 10% of the combined company’s revenues and EBITDA, signalling a meaningful expansion of the group’s presence in healthcare applications.

Market reaction to the announcement

Advanced Medical Solutions’ shares rose sharply after the cash offer was announced. The stock traded around 275–278 pence, reflecting a strong positive price reaction relative to prior trading levels before the offer became public.

The move in the share price indicates that the market is aligning expectations with the proposed £2.85 per share offer terms, while still incorporating the time and conditionality attached to the planned completion by the end of 2026.

Key Takeaways

01The proposed acquisition marks a sizeable expansion of H.B. Fuller into medical adhesives, creating a dedicated unit with meaningful scale in group results.
02Shareholder and regulatory approvals are central to the outcome, with completion not expected until late 2026, underscoring the long horizon for deal closure.
03The strong share price reaction of Advanced Medical Solutions signals investor attention to the cash premium embedded in the £2.85 per share offer.

References